The E23K polymorphism of the pancreatic beta-cell ATP-sensitive K(+) (K(ATP)) channel subunit Kir6.2 (KCNJ11) is associated with type 2 diabetes in whites, and a recent in vitro study of the E23K variant suggests that the association to diabetes might be explained by a slight inhibition of serum insulin release. In a study comprising 519 unrelated glucose-tolerant subjects, we addressed the question as to whether the E23K variant was related to reduced serum insulin release during an oral glucose tolerance test (OGTT). Furthermore, the polymorphism was examined in a case-control study comprising 803 type 2 diabetic patients and 862 glucose-tolerant control subjects. The E23K variant was associated with significant reductions in the insulinogenic index (P = 0.022) and serum insulin levels under the response curve during an OGTT (0-120 min) (P = 0.014) as well as with an increase in BMI (P = 0.013). In the present study, the association of the E23K polymorphism with type 2 diabetes was not significant (P = 0.26). However, the K23K genotype significantly associated with type 2 diabetes in a meta-analysis of white case and control subjects (n = 2,824, odds ratio [OR] 1.49, P = 0.00022). In conclusion, the widespread E23K polymorphism may have a diabetogenic effect by impairing glucose-induced insulin release and increasing BMI.

Download full-text PDF

Source
http://dx.doi.org/10.2337/diabetes.52.2.573DOI Listing

Publication Analysis

Top Keywords

e23k variant
16
serum insulin
16
type diabetes
16
e23k polymorphism
12
insulin release
12
associated type
8
study comprising
8
control subjects
8
e23k
7
insulin
5

Similar Publications

Article Synopsis
  • The study investigates the activation and stability of factor XIII subunit FXIII-A, focusing on its unique activation peptide (AP) and how specific mutations affect its function.
  • Recombinant FXIII-A AP variants were created to analyze their role in thrombin activation and transglutaminase activity, using techniques like SDS-PAGE and mass spectrometry for assessment.
  • Key findings highlight that certain mutations to the activation peptide impair FXIII-A stability and activation, indicating that specific amino acid interactions are essential for its functionality in the coagulation process.
View Article and Find Full Text PDF

Structural Studies of Inhibitors with Clinically Relevant Influenza Endonuclease Variants.

Biochemistry

February 2024

Department of Chemistry and Biochemistry, University of California, La Jolla, California 92093, United States.

Vital to the treatment of influenza is the use of antivirals such as Oseltamivir (Tamiflu) and Zanamivir (Relenza); however, antiviral resistance is becoming an increasing problem for these therapeutics. The RNA-dependent RNA polymerase acidic N-terminal (PA) endonuclease, a critical component of influenza viral replication machinery, is an antiviral target that was recently validated with the approval of Baloxavir Marboxil (BXM). Despite its clinical success, BXM has demonstrated susceptibility to resistance mutations, specifically the I38T, E23K, and A36 V mutants of PA.

View Article and Find Full Text PDF
Article Synopsis
  • The COVID-19 pandemic, caused by SARS-CoV-2, has resulted in over 6 million deaths, with high variability in symptoms linked to genetic and environmental factors.
  • Researchers studied the ACE2 gene, which encodes the cell entry receptor for the virus, to see how its variations (polymorphisms) affect infection rates and symptom severity.
  • Certain ACE2 variants increased the risk of severe COVID-19 by promoting infection, while others appeared to offer protection, particularly in Asian populations, potentially explaining lower mortality rates there.
View Article and Find Full Text PDF

Duration of fever and symptoms in influenza-infected children treated with baloxavir marboxil during the 2019-2020 season in Japan and detection of influenza virus with the PA E23K substitution.

Antiviral Res

May 2022

Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan; Infectious Disease Research Center at Niigata University in Myanmar (IDRC), Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.

Article Synopsis
  • A study was conducted to compare the effectiveness of baloxavir marboxil and oseltamivir in treating children with influenza A and B, focusing on the duration of fever and symptoms.
  • The research included 159 patients under 19 years old from Japan during the 2019-2020 flu season, using specific statistical methods to analyze the data.
  • Results indicated that the duration of fever was shorter for patients treated with baloxavir compared to those treated with oseltamivir, though further evaluation on baloxavir’s effectiveness and virus susceptibility is needed.
View Article and Find Full Text PDF

COVID-19 is a respiratory illness caused by a novel coronavirus called SARS-CoV-2. The viral spike (S) protein engages the human angiotensin-converting enzyme 2 (ACE2) receptor to invade host cells with ~10-15-fold higher affinity compared to SARS-CoV S-protein, making it highly infectious. Here, we assessed if ACE2 polymorphisms can alter host susceptibility to SARS-CoV-2 by affecting this interaction.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!